Cargando…
Monoamine Levels and Parkinson’s Disease Progression: Evidence From a High-Performance Liquid Chromatography Study
Parkinson’s disease (PD) is associated with dysfunction of monoamine neurotransmitter systems. We investigated changes in the levels of monoamine and their metabolites in PD patients, together with their association to clinical profiles. PD patients and age-matched control subjects (n = 40 per group...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358115/ https://www.ncbi.nlm.nih.gov/pubmed/34393700 http://dx.doi.org/10.3389/fnins.2021.605887 |
_version_ | 1783737269442576384 |
---|---|
author | Wichit, Patsorn Thanprasertsuk, Sekh Phokaewvarangkul, Onanong Bhidayasiri, Roongroj Bongsebandhu-phubhakdi, Saknan |
author_facet | Wichit, Patsorn Thanprasertsuk, Sekh Phokaewvarangkul, Onanong Bhidayasiri, Roongroj Bongsebandhu-phubhakdi, Saknan |
author_sort | Wichit, Patsorn |
collection | PubMed |
description | Parkinson’s disease (PD) is associated with dysfunction of monoamine neurotransmitter systems. We investigated changes in the levels of monoamine and their metabolites in PD patients, together with their association to clinical profiles. PD patients and age-matched control subjects (n = 40 per group) were enrolled. Using high-performance liquid chromatography (HPLC) with an electrochemical detector, levels of monoamines (dopamine, DA; norepinephrine, NE; epinephrine, EPI; and serotonin, 5-HT) were measured in plasma, while the metabolites (homovanillic acid, HVA; vanillylmandelic acid, VMA; and 5-hydroxyindoleacetic acid, 5-HIAA) were measured in urine. Plasma DA level was not significantly different between PD and control groups. PD patients had significantly higher plasma NE but lower EPI and 5-HT levels. PD patients had a significantly higher HVA/DA ratio and lower VMA/NE ratio than control subjects, while the 5-HIAA/5-HT ratio was not different between the groups. Regarding the association between monoamine levels and clinical profiles, the DA level had a negative relationship with disease duration and the 5-HT level had a negative relationship with severity of motor impairment. These findings emphasized the involvements of several neurotransmission systems and their association with clinical profiles in PD patients, demonstrated by quantification of monoamine levels in peripheral body fluids. This could benefit appropriate pharmacological treatment planning in respect of monoamine changes and might also help predict subsequent clinical symptoms. |
format | Online Article Text |
id | pubmed-8358115 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83581152021-08-13 Monoamine Levels and Parkinson’s Disease Progression: Evidence From a High-Performance Liquid Chromatography Study Wichit, Patsorn Thanprasertsuk, Sekh Phokaewvarangkul, Onanong Bhidayasiri, Roongroj Bongsebandhu-phubhakdi, Saknan Front Neurosci Neuroscience Parkinson’s disease (PD) is associated with dysfunction of monoamine neurotransmitter systems. We investigated changes in the levels of monoamine and their metabolites in PD patients, together with their association to clinical profiles. PD patients and age-matched control subjects (n = 40 per group) were enrolled. Using high-performance liquid chromatography (HPLC) with an electrochemical detector, levels of monoamines (dopamine, DA; norepinephrine, NE; epinephrine, EPI; and serotonin, 5-HT) were measured in plasma, while the metabolites (homovanillic acid, HVA; vanillylmandelic acid, VMA; and 5-hydroxyindoleacetic acid, 5-HIAA) were measured in urine. Plasma DA level was not significantly different between PD and control groups. PD patients had significantly higher plasma NE but lower EPI and 5-HT levels. PD patients had a significantly higher HVA/DA ratio and lower VMA/NE ratio than control subjects, while the 5-HIAA/5-HT ratio was not different between the groups. Regarding the association between monoamine levels and clinical profiles, the DA level had a negative relationship with disease duration and the 5-HT level had a negative relationship with severity of motor impairment. These findings emphasized the involvements of several neurotransmission systems and their association with clinical profiles in PD patients, demonstrated by quantification of monoamine levels in peripheral body fluids. This could benefit appropriate pharmacological treatment planning in respect of monoamine changes and might also help predict subsequent clinical symptoms. Frontiers Media S.A. 2021-07-29 /pmc/articles/PMC8358115/ /pubmed/34393700 http://dx.doi.org/10.3389/fnins.2021.605887 Text en Copyright © 2021 Wichit, Thanprasertsuk, Phokaewvarangkul, Bhidayasiri and Bongsebandhu-phubhakdi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Wichit, Patsorn Thanprasertsuk, Sekh Phokaewvarangkul, Onanong Bhidayasiri, Roongroj Bongsebandhu-phubhakdi, Saknan Monoamine Levels and Parkinson’s Disease Progression: Evidence From a High-Performance Liquid Chromatography Study |
title | Monoamine Levels and Parkinson’s Disease Progression: Evidence From a High-Performance Liquid Chromatography Study |
title_full | Monoamine Levels and Parkinson’s Disease Progression: Evidence From a High-Performance Liquid Chromatography Study |
title_fullStr | Monoamine Levels and Parkinson’s Disease Progression: Evidence From a High-Performance Liquid Chromatography Study |
title_full_unstemmed | Monoamine Levels and Parkinson’s Disease Progression: Evidence From a High-Performance Liquid Chromatography Study |
title_short | Monoamine Levels and Parkinson’s Disease Progression: Evidence From a High-Performance Liquid Chromatography Study |
title_sort | monoamine levels and parkinson’s disease progression: evidence from a high-performance liquid chromatography study |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358115/ https://www.ncbi.nlm.nih.gov/pubmed/34393700 http://dx.doi.org/10.3389/fnins.2021.605887 |
work_keys_str_mv | AT wichitpatsorn monoaminelevelsandparkinsonsdiseaseprogressionevidencefromahighperformanceliquidchromatographystudy AT thanprasertsuksekh monoaminelevelsandparkinsonsdiseaseprogressionevidencefromahighperformanceliquidchromatographystudy AT phokaewvarangkulonanong monoaminelevelsandparkinsonsdiseaseprogressionevidencefromahighperformanceliquidchromatographystudy AT bhidayasiriroongroj monoaminelevelsandparkinsonsdiseaseprogressionevidencefromahighperformanceliquidchromatographystudy AT bongsebandhuphubhakdisaknan monoaminelevelsandparkinsonsdiseaseprogressionevidencefromahighperformanceliquidchromatographystudy |